Deals Of The Week: Sanofi/TargeGen, Arena/Eisai, GSK/Genmab ...
Executive Summary
Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at 1http://invivoblog.blogspot.com/.
You may also be interested in...
Genmab Reins In, Looks To Partners
Once hailed by some as a potential "European Genentech," antibody player Genmab AS is emerging far humbler from the other side of a radical strategic and financial overhaul. Hit by a series of development delays, cost overruns and some poor decision-making, the company has reined in its one-time ambition to become a fully integrated, commercial outfit.
Genmab Reins In, Looks To Partners
Once hailed by some as a potential "European Genentech," antibody player Genmab AS is emerging far humbler from the other side of a radical strategic and financial overhaul. Hit by a series of development delays, cost overruns and some poor decision-making, the company has reined in its one-time ambition to become a fully integrated, commercial outfit.
Lundbeck’s New Partners: Research With Genmab, Marketing With Merck
Lundbeck has entered into a research collaboration with fellow Danish company Genmab, its first since announcing a new R&D strategy in September. It’s the second collaboration for Genmab since that company also updated its corporate strategy at around the same time.